Jon Congleton, Mineralys Therapeutics CEO
January 19, 2023 11:27 AM ESTUpdated 03:40 PM
Financing
Startups

Af­ter hy­per­ten­sion com­peti­tor gets bought, Min­eralys lines up IPO plans

Kyle LaHucik

Senior Reporter

Min­eralys Ther­a­peu­tics has pen­ciled in a $100 mil­lion ini­tial pub­lic of­fer­ing to take its in­ves­ti­ga­tion­al hy­per­ten­sion drug in­to Phase III test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times